Teva Gets Investment From Royalty On Olanzapine LAI

Follows Successful Launch Of Uzedy LAI Risperidone In The US Earlier This Year

 
• By Dave Wallace

Teva has announced a new investment from Royalty Pharma in its long-acting injectable formulation of olanzapine that is being developed for the US market with partner MedinCell.

Dollar sign wearing crown with gold background
Teva has garnered investment from Royalty in olanzapine LAI • Source: Shutterstock

More from Deals

More from Business